Home › Congenital Heart Defects › NCT06932081
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Congenital heart defect. * Age ≥ 18 years. * Initiated on treatment with an SGLT2i. Exclusion Criteria: \- No consent for data collection.
About the study
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
What is being tested
- SGLT2 inhibitors (drug)
Sponsor: Leiden University Medical Center · Participants: 400 · Started: Jan 1, 2023
Contact the study team
- Ralph M.L. Neijenhuis, MD · Phone: +31 71 5262020
- Björn N. Westdorp, MD · Phone: +31 71 5262020
Official record on ClinicalTrials.gov — NCT06932081
Locations in the U.S.
| Maryland | Johns Hopkins University, Baltimore |
| Michigan | Helen DeVos Children's Hospital, Grand Rapids |
| New York | Mount Sinai Fuster Heart Hospital, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.